Chapter 19. Diagnosis and Management of Acquired Bleeding Disorders: Vitamin K Antagonists

  1. Mark A. Crowther MD, MSc, FRCPC Professor Division Director2,3,
  2. Jeff Ginsberg MD, FRCPC Professor4,
  3. Holger J. Schünemann MD, PhD, MSc, FACP, FCCP Professor5,6,
  4. Ralph M. Meyer MD, FRCPC Director Professor7,8 and
  5. Richard Lottenberg MD, FACP Professor9
  1. Miguel A. Escobar MD

Published Online: 4 FEB 2009

DOI: 10.1002/9781444300857.ch19

Evidence-Based Hematology

Evidence-Based Hematology

How to Cite

Escobar, M. A. (2008) Diagnosis and Management of Acquired Bleeding Disorders: Vitamin K Antagonists, in Evidence-Based Hematology (eds M. A. Crowther, J. Ginsberg, H. J. Schünemann, R. M. Meyer and R. Lottenberg), Wiley-Blackwell, Oxford, UK. doi: 10.1002/9781444300857.ch19

Editor Information

  1. 2

    Division of Hematology, McMaster University, Hamilton, Ontario, Canada

  2. 3

    St. Joseph's Hospital, Hamilton, Ontario, Canada

  3. 4

    Department of Medicine, McMaster University, Hamilton, Canada

  4. 5

    CLARITY Research Group, Department of Epidemiology, Italian National Cancer Institute Regina Elena, Rome, Italy

  5. 6

    McMaster University, Hamilton, Canada

  6. 7

    National Cancer Institute of Canada, Clinical Trials Group, Edith Eisenhauer Chair in Clinical Cancer Research, Queen's University, Kingston, Ontario, Canada

  7. 8

    Departments of Oncology and Medicine, Queen's University, Kingston, Ontario, Canada

  8. 9

    Division of Hematology/Oncology, Department of Medicine, University of Florida College of Medicine, Gainesville, Florida, USA

Author Information

  1. Department of Pediatrics and Internal Medicine, Division of Hematology, University of Texas Health Science Center at Houston, Houston, Texas, USA

Publication History

  1. Published Online: 4 FEB 2009
  2. Published Print: 27 JUN 2008

ISBN Information

Print ISBN: 9781405157476

Online ISBN: 9781444300857

SEARCH

Keywords:

  • acquired bleeding disorders;
  • length of therapy;
  • actual risk of bleeding and use of vitamin K antagonists;
  • cumulative incidence of major bleeding;
  • role of subcutaneous vitamin K;
  • recommended dose of oral Vitamin K;
  • management of nonbleeding patient;
  • management of bleeding patient;
  • coagulopathy due to VKAs - common problem in outpatient clinics

Summary

This chapter contains sections titled:

  • What is the risk of bleeding with the use of vitamin K antagonists?

  • Can we calculate the actual risk of bleeding with the use of vitamin K antagonists?

  • What is the recommended management for bleeding due to vitamin K antagonists?

  • Is there a role for subcutaneous vitamin K?

  • What is the recommended dose of oral Vitamin K?

  • Conclusions

  • References